// App-Quantinova.ai

: Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Researchers

Presenter

  • Regis Peffault De Latour

Principal Investigators

  • Jaroslaw P. Maciejewski

  • Austin G. Kulasekararaj

  • Loree Larratt

  • Ronald S. Go

  • David Dingli

  • Amanda Wilson

  • Philippe Gustovic

  • Aleksandr Kulagin

Medical Centers

  • Universite Paris Descartes, Paris, France

  • French Reference Center for Aplastic Anemia and PNH Hematology-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • Department of Haematological Medicine,King’s College Hospital, NIHR/Wellcome King’s Clinical Research Facility,London,United Kingdom

  • Department of Internal Medicine, University of Alberta, Edmonton, AB, Canada

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Alexion Pharmaceuticals, Inc., Lexington, MA

  • Alexion Pharma GmbH, Zurich, Switzerland

  • Pavlov First Saint Petersburg State Medical University, Saint‐Petersburg, Russian Federation

Locations

  • France

  • United States

  • United Kingdom

  • Canada

  • Switzerland

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • NCT01374360

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved